We identified 97,436 eligible Medicare beneficiaries with T2D and initiated an SGLT2 inhibitor or DPP4 inhibitor during 2017–2018, of which 80,949 (83.1%) were DPP4 inhibitor users and 16,487 (16.9%) were SGLT2 inhibitor users. Here, SLC5A2 is linked to type 2 diabetes mellitus.